Naloxone Market – Manufacturing Cost Structure, Top Vendors, Product Category, By Requirements 2027
Apr 10, 2021 (Market Insight Reports) -- Naloxone Market- Insights Naloxone is an opioid antagonist used for the treatment of opioid overdose such as of...
Market Insight Reports · 2d ago
Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
GlobeNewswire · 6d ago
Distributed Antenna Systems Market Business Overview, Risks And Opportunities with COVID-19 Scenario to 2031|AT&T, American Tower Corporation, Cobham Wireless
Apr 05, 2021 (WiredRelease via Comtex) -- The studies on worldwide Distributed Antenna Systems market evaluates the capabilities, organizations,... · 04/05 09:50
Amphastar Pharmaceuticals Stock Gives Every Indication Of Being Modestly Undervalued
GuruFocus News · 04/02 13:12
Lidocaine Hydrochloride Market 2021 Size, Share, Analysis, Demand, Growth Driver and Industry Segments by 2027
Market Insight Reports · 04/01 21:46
FDA Approves New Drug Application For Amphastar’s Dextrose Injection
Amphastar Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Dextrose injection 50% in the 50 ml Luer-Jet Prefilled Syringe System. Amphastar (AMPH) has sold and marketed th...
SmarterAnalyst · 03/30 12:14
Amphastar Pharmaceuticals (AMPH) Receives a Buy from Northland Securities
In a report released yesterday, Tim Chiang from Northland Securities maintained a Buy rating on Amphastar Pharmaceuticals (AMPH), with a price target of
SmarterAnalyst · 03/30 11:55
Amphastar Pharma shares gain on FDA approval for Dextrose injection
The FDA has approved Amphastar Pharmaceuticals' (AMPH) Abbreviated New Drug Application ((ANDA)) for Dextrose injection 50% in the 50 mL Luer-Jet Prefilled Syringe System.For the past 40 years, the company has
Seekingalpha · 03/29 11:57
BRIEF-Amphastar Pharmaceuticals Receives FDA Approval For Dextrose Injection · 03/29 11:24
DJ Amphastar Pharmaceuticals Shares Rise on FDA Approval for Dextrose Injection
Dow Jones · 03/29 10:31
Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") approved the Company's Abbreviated New Drug Application ("ANDA") for Dextrose
Benzinga · 03/29 10:01
Global Lidocaine Hydrochloride Market 2020 with Covid-19 Impact Analysis and Forecast by 2025
Mar 21, 2021 (CDN Newswire via Comtex) -- proclaims the addition of a new report titled Global Lidocaine Hydrochloride Market 2020 by...
CDN Newswire · 03/21 17:35
Insider Trends: Insider at Amphastar Pharmaceuticals Gets Shares Award Sells Portion for Taxes
MT Newswires · 03/18 21:19
Insider Trends: Insider at Amphastar Pharmaceuticals Awarded Shares Portion of Which is Sold for Taxes
MT Newswires · 03/18 20:55
New Strong Sell Stocks for March 18th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Zacks · 03/18 13:05
Insider Trends: Insider at Amphastar Pharmaceuticals Makes Tax Sale Extends 90-Day Selling Trend
MT Newswires · 03/17 19:53
DJ Amphastar Pharmaceuticals Price Target Cut to $20.00/Share From $21.00 by Wells Fargo
Dow Jones · 03/17 12:16
DJ Amphastar Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 03/17 12:16
Wells Fargo Maintains Equal-Weight on Amphastar Pharmaceuticals, Lowers Price Target to $20
Wells Fargo maintains Amphastar Pharmaceuticals (NASDAQ:AMPH) with a Equal-Weight and lowers the price target from $21 to $20.
Benzinga · 03/17 12:07
--Analyst Actions: Wells Fargo Adjusts Price Target on Amphastar Pharmaceuticals to $20 From $21, Maintains Equal-Weight Rating
MT Newswires · 03/17 10:41
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharms through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.